| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/22/2003 | EP1276907A2 Viral vectors for use in monitoring hiv drug resistance |
| 01/22/2003 | EP1276896A2 Method of identifying and producing antigen peptides and use thereof as vaccines |
| 01/22/2003 | EP1276893A1 Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same |
| 01/22/2003 | EP1276872A2 A thymus expressed human cytochrome p450 (p450tec) |
| 01/22/2003 | EP1276863A1 Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof |
| 01/22/2003 | EP1276856A1 Albumin fusion proteins |
| 01/22/2003 | EP1276853A1 Pneumovirus ns proteins antagonising the interferon (ifn) response |
| 01/22/2003 | EP1276852A2 Viruses comprising mutated ion channel protein |
| 01/22/2003 | EP1276849A2 Albumin fusion proteins |
| 01/22/2003 | EP1276770A1 Proteins with a high immunoreactivity and a method for the production thereof |
| 01/22/2003 | EP1276762A1 Porphyromonas gingivalis recombinant proteins and truncations |
| 01/22/2003 | EP1276757A1 ANTIGENIC PEPTIDE FRAGMENTS OF VapA PROTEIN, AND USES THEREOF |
| 01/22/2003 | EP1276501A2 Method for treatment of tumors using photodynamic therapy |
| 01/22/2003 | EP1276499A2 Equine protozoal myeloencephalitis vaccine |
| 01/22/2003 | EP1276496A2 Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor |
| 01/22/2003 | EP1276490A1 Novel borrelia burgdorferi polypeptides and uses thereof |
| 01/22/2003 | EP1276468A1 Use of particulate vectors in immunomodulation |
| 01/22/2003 | EP0627004B1 Improvements in or relating to malaria vaccine |
| 01/22/2003 | EP0610436B1 Hepatitis-c virus testing |
| 01/22/2003 | CN1392798A Mimetic peptides for epitope of apolipoprotein B-100, concatemer and modified peptides, and vaccine composition comprising same |
| 01/22/2003 | CN1392254A Recombined adenovirus and its use in curing myocardial ischemia |
| 01/22/2003 | CN1391954A Composition for reinforcing nucleic acid vaccine immunity and its producing method and using method |
| 01/22/2003 | CN1099460C Chicken merek's disease virus genic mutant strain and its use |
| 01/22/2003 | CN1099296C Compositions including calcium influx retardant for inhibiting cell growth |
| 01/22/2003 | CN1099295C Infectious cloacal bursa virus vaccine for chicken and its preparing process and application |
| 01/21/2003 | US6509458 Gene expressed in prostate cancer |
| 01/21/2003 | US6509449 To provide a detection method for assaying the polypeptide using the monoclonal antibody |
| 01/21/2003 | US6509446 Recombinant genetic information (DNA or RNA), consisting a Chicken Anemia Virus (CAV)-specific nucleotide sequence, useful for diagonestics, vaccination or protein production |
| 01/21/2003 | US6509313 Stimulation of immune response with low doses of cytokines |
| 01/21/2003 | US6509151 DNA molecule encoding a Mycobacterium protein and conferring on Mycobacterium tuberculosis an ability to enter mammalian cells and to survive within macrophages |
| 01/21/2003 | US6509033 Immunomodulatory peptides |
| 01/21/2003 | US6509020 Replication-competent herpes simplex virus |
| 01/21/2003 | US6509019 Immunologically active proteins from Borrelia burgdorferi |
| 01/21/2003 | US6509018 Expressed peptides, in particular a strain designated YBF30; including V3 loop region and corresponding nucleotide sequences |
| 01/21/2003 | US6509017 Vaccines containing nucleic acid fragments encoding antigenic proteins that increase resistance to infection; isolated, purified polypeptide having amino acid sequence 1-598 of seq id no: 6 or 1-600 of seq id no: 8 |
| 01/21/2003 | US6509016 Delaying recurrence of ganglioside 2 associated tumors; antibody comprising the light and heavy chain variable region sequences contained in seq id no: 2 and 4 |
| 01/21/2003 | US6509015 Human antibodies that bind human TNFa |
| 01/21/2003 | US6509014 Therapeutic/cosmetic compositions comprising CGRP antagonists for treating skin redness/rosacea/discreet erythema |
| 01/21/2003 | CA2204253C Methods and devices for immunizing a host through administration of naked polynucleotides which encode antigenic peptides |
| 01/21/2003 | CA2106952C A single dose vaccination system |
| 01/21/2003 | CA2098720C Cellular composition for the treatment of human or animal organisms |
| 01/21/2003 | CA2096529C Recombinant avirulent salmonella antifertility vaccines |
| 01/18/2003 | CA2352702A1 Novel human proton gated ion channel |
| 01/16/2003 | WO2003005636A1 Secure header information for multi-content e-mail |
| 01/16/2003 | WO2003005035A1 Chp for use as marker for sepsis-type inflammatory diseases |
| 01/16/2003 | WO2003004684A2 NUCLEIC ACIDS ENCODING A RECOMBINANT 250 kDa ANTIGEN FROM SPOROZOITES/MEROZOITES OF EIMERIA MAXIMA AND THEIR USES |
| 01/16/2003 | WO2003004683A2 Nucleic acids encoding recombinant 56 and 82 kda antigens from gametocytes of eimeria maxima and their uses |
| 01/16/2003 | WO2003004661A2 Adenovital vectors with cell type specificity for mesenchymal cells |
| 01/16/2003 | WO2003004657A1 Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof |
| 01/16/2003 | WO2003004651A1 Novel surface exposed immunoglobulin d-binding protein from moraxella catarrhalis |
| 01/16/2003 | WO2003004650A2 Group b streptococcus antigens and corresponding dna fragments |
| 01/16/2003 | WO2003004648A1 Anti_human ovarian cancer -anti_cd3 bispecific antibody |
| 01/16/2003 | WO2003004627A2 Novel human hepatoma lines, methods for obtaining same and uses thereof |
| 01/16/2003 | WO2003004620A2 Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| 01/16/2003 | WO2003004615A2 Secreted proteins |
| 01/16/2003 | WO2003004608A2 Drug metabolizing enzymes |
| 01/16/2003 | WO2003004607A2 Aggrecanase molecules |
| 01/16/2003 | WO2003004604A2 Phage displayed pdz domain ligands |
| 01/16/2003 | WO2003004533A1 Immunological binding molecules inhibiting the syncytial fusion of trophoblast cells |
| 01/16/2003 | WO2003004526A2 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and their use as medicines |
| 01/16/2003 | WO2003004525A2 Isolation and purification of plasmodium falciparum merozoite protein-142 |
| 01/16/2003 | WO2003004524A2 Apicomplexa parasites secreted proteins |
| 01/16/2003 | WO2003004520A2 Mycobacterial antigens expressed during latency |
| 01/16/2003 | WO2003004519A1 Icosahedral superstructures of vp2 of infectious bursitis virus (ibdv) and the applications thereof |
| 01/16/2003 | WO2003004517A2 Peyers's patch and/or m-celle targeting ligands |
| 01/16/2003 | WO2003004056A1 Method for treating multiple myeloma |
| 01/16/2003 | WO2003004055A2 Nucleic acid adjuvants |
| 01/16/2003 | WO2003004054A1 Ltb4 as vaccine aduvant |
| 01/16/2003 | WO2003004053A1 Methods for inducing an immune response with an elevated th1/th2 ratio, by intracellular induction of nfkappab |
| 01/16/2003 | WO2003004052A1 Mycoplasma bovis vaccine and methods of reducing pneumonia in animals |
| 01/16/2003 | WO2003004051A2 Mycoplasma hyopneumoniae vaccine and methods for reducing mycoplasma bovis pneumonia in cattle |
| 01/16/2003 | WO2003004050A1 Methylation of histone h4 at arginine 3 |
| 01/16/2003 | WO2003004049A2 Use of polyclonal anti-hiv goat serum as a therapeutic agent |
| 01/16/2003 | WO2003004037A1 Xenogenic oligoor/and polyribonucleotides as agents for the treatment of malignant tumours |
| 01/16/2003 | WO2003004004A1 Pharmacological preparation made from a nanoparticulate mesomorphous polyelectrolyte lipid complex and at least one active ingredient |
| 01/16/2003 | WO2003003986A2 Parathyroid hormone antibodies and related methods |
| 01/16/2003 | WO2003003985A2 Polyvalent conjugate vaccine for cancer |
| 01/16/2003 | WO2003003975A2 Detection and therapy of vulnerable plaque with photodynamic compounds |
| 01/16/2003 | WO2003003941A2 One dose vaccination with mycoplasma hyopneumoniae |
| 01/16/2003 | WO2003003906A2 Diagnostic and screening methods for bladder cancer |
| 01/16/2003 | WO2002094194A3 Compositions and methods for inhibiting metastasis |
| 01/16/2003 | WO2002088178A3 Antigens of group b streptococcus and corresponding dna fragments |
| 01/16/2003 | WO2002062379A3 Clostridium difficile vaccine |
| 01/16/2003 | WO2002059148A8 A method for identification, isolation and production of antigens to a specific pathogen |
| 01/16/2003 | WO2002044343A3 Tolerizing allografts of pluripotent stem cells |
| 01/16/2003 | WO2002043661A3 Recombinant anti-cd30 antibodies and uses thereof |
| 01/16/2003 | WO2002040540A3 Artery smooth muscle- and vein smooth muscle-specific proteins and uses therefor |
| 01/16/2003 | WO2002038177A3 Adjuvant combination formulations |
| 01/16/2003 | WO2002038176A3 Immunogenic compositions comprising liver stage malarial antigens |
| 01/16/2003 | WO2002038172A3 Sdf-1 beta expressing tumor cells as tumor vaccines |
| 01/16/2003 | WO2002034771A3 Nucleic acids and proteins from streptococcus groups a & b |
| 01/16/2003 | WO2002034769A3 Immunoreactive peptide ctl epitopes of human cytomegalovirus pp150 |
| 01/16/2003 | WO2002034287A3 Therapeutic vaccine formulations containing chitosan |
| 01/16/2003 | WO2002022080A8 Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications |
| 01/16/2003 | WO2002021141A3 Methods and compositions for diseases associated with amyloidosis |
| 01/16/2003 | WO2002020813A3 Recombinant endothelial cell growth inhibitors derived from a mammalian plasminogen |
| 01/16/2003 | WO2002020047A3 Chlamydial peptides and their mimics in demyelinating disease |
| 01/16/2003 | WO2002016595A3 Kidney-specific protein |
| 01/16/2003 | WO2002014352A3 Therapeutic compounds for ovarian cancer |
| 01/16/2003 | WO2002004021A9 Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications |